Most first-occurrence, second-degree atrioventricular blocks were observed less than six hours after the first dose, according to the researchers. No Mobitz II or third-degree atrioventricular blocks were reported in FIRST or FREEDOMS II.
It is difficult to identify which patients should receive fingolimod, but less difficult to identify patients who should not receive it, said Robert P. Lisak, MD, Professor of Neurology at Wayne State University in Detroit and President-Elect of CMSC. “But once they’re on it, and if they don’t have other contraindications, they should be OK.”
—Naseem S. Miller
IMNG Medical News